Oluwadamilola Fayanju, MD, MA, MPHS

Lola_Fayanju.jpg
Associate Director, Disparities & Value in Healthcare
 
Assistant Professor of Surgery, Duke University School of Medicine
Assistant Professor of Population Health Sciences, Duke University School of Medicine
Surgical Lead, Duke Inflammatory Breast Cancer Clinic
Director, Durham VA Breast Clinic

Dr. Oluwadamilola "Lola" Fayanju is an Assistant Professor of Surgery and Population Health Sciences in the Duke University School of Medicine. She is also the surgical lead for the Inflammatory Breast Cancer (IBC) Clinic at the Duke Cancer Institute and Director of the Breast Clinic at the Durham VA Medical Center.

She received both her undergraduate degree in History and Science and a master of arts in Comparative Literature from Harvard. She received her medical degree and a master of population health sciences (MPHS) from Washington University in St. Louis, where she also completed her residency in general surgery. She completed fellowship training in Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Fayanju has a strong and long-standing commitment to promoting the equity and efficacy with which breast cancer patients are treated, a guiding principle that is reflected in her clinical practice and research endeavors. She is an academic breast surgeon who conducts health services research focused on addressing disparities in breast cancer outcome and treatment as well as improving the quality and efficiency of breast cancer care delivery using the principles of value-based health care. In 2019, she was recognized by the National Academy of Medicine (NAM) as an Emerging Leader in Health and Medicine Scholar, selected as one of 10 early- and mid-career researchers nationwide felt to “represent the next generation of leading scientists, health care providers, public health professionals, and policymakers.” Her research has been recognized with the receipt of two Conquer Cancer Merit Awards from the American Society of Clinical Oncology (ASCO) and is currently supported by a K08 career development award from the National Institutes of Health (NIH).